2026/06/12
We are reaching out to make you aware of a decisive action we are taking to address the U.S. Department of Defense’s erroneous designation of our company, and to protect the interests of our customers, partners, employees and shareholders.
Read more2026/06/09
We want to be absolutely clear: WuXi AppTec is not a Chinese military company — not based on an objective review of the facts, and not under the statutory designation criteria for the Section 1260H list under U.S. law.
Read more2026/05/17
WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), which recognizes the top-performing companies in each industry on long-term sustainability criteria. This recognition reflects progress that WuXi AppTec has made in integrating responsible sustainability practices across its operations and strategies.
Read more2026/04/27
(SHANGHAI, April 27, 2026) – WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 (“Reporting Period”).
Read more2026/03/23
(SHANGHAI, March 23, 2026) – WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the full year ended December 31, 2025 (“Reporting Period”).
Read more